fda compounding glp-1 enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our How FDA Crackdowns Are Affecting

These include dietary interventions, orlistat, lorcaserin, phentermine/topiramate, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, pramlintide, dapagliflozin, the duodenaljejunal bypass liner, gastric pacemakers and gastric balloons

Supports Energy Levels: Ingredients such as thiamin, vitamin B6, and coenzyme Q10 help boost and maintain energy levels throughout the day

Transparent pricing and discreet home delivery.

Explore our non-surgical options

Constipation is a common side effect of Ozempic

body composition, nutrient levels, and metabolic markers are critical in determining treatment and possible tapering.Not everyone needs to take GLP-1s forevertapering is possible, but it depends on individual health markers, genetics, and whether metabolic signals are balanced.The future of metabolic health lies in combination therapies that target multiple pathways, not just GLP-1s.Dieting alone disrupts metabolic signals, making professional metabolic medicine and nutrition guidance essential for long-term health.Resources:Connect with Dr